Debrisoquine - Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 14:03, 8 August 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 14:03, 8 August 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Debrisoquine
Names

IUPAC name 1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
Identifiers
CAS Number	1131-64-2
3D model (JSmol)	Interactive image
ChEBI	CHEBI:34665
ChEMBL	ChEMBL169901
ChemSpider	2860
DrugBank	DB04840
ECHA InfoCard	100.013.155
KEGG	C13650
MeSH	Debrisoquine
PubChem CID	2966
UNII	X31CDK040E
CompTox Dashboard (EPA)	DTXSID7022885
InChI InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)Key: JWPGJSVJDAJRLW-UHFFFAOYSA-N InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)Key: JWPGJSVJDAJRLW-UHFFFAOYAE
SMILES =C(N)N2Cc1c(cccc1)CC2
Properties
Chemical formula	C₁₀H₁₃N₃
Molar mass	175.23032
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is ?) Infobox references

Chemical compound

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.

References

Debrisoquine - Compound Summary, PubChem.
Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach

Sympatholytic (and closely related) antihypertensives (C02)

Sympatholytics
(antagonize α-adrenergic
vasoconstriction)

Central

α₂-Adrenergic receptor agonists	Clonidine Guanabenz Guanfacine Guanoxabenz Methyldopa Tiamenidine
Adrenergic release inhibitors	Bethanidine Bretylium Debrisoquine Guanadrel Guanazodine Guancydine Guanethidine Guanoclor Guanoxan
Imidazoline receptor agonists	Moxonidine Rilmenidine Tolonidine
Ganglion-blocking/nicotinic antagonists	Hexamethonium Mecamylamine Pentolinium Trimethaphan

Peripheral

Indirect

Monoamine oxidase inhibitors	Pargyline
VMAT inhibitors	Bietaserpine Deserpidine Methoserpidine Reserpine Syrosingopine
Tyrosine hydroxylase inhibitors	Metirosine

Direct

α₁-Adrenergic receptor blockers	Doxazosin Ketanserin Indoramin Prazosin Trimazosin Urapidil
Non-selective α-adrenergic receptor blockers	Phentolamine

Other antagonists

Serotonin receptor antagonists	Ketanserin Lidanserin
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension)	dual (Aprocitentan, Bosentan, Macitentan (+tadalafil), Riociguat) selective (Ambrisentan (+tadalafil), Sitaxentan, Sotatercept)

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:

See also

References